Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.59
-0.74 (-4.04%)
Feb 11, 2026, 1:16 PM EST - Market open
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,372 employees as of December 31, 2024. The number of employees increased by 58 or 4.41% compared to the previous year.
Employees
1,372
Change (1Y)
58
Growth (1Y)
4.41%
Revenue / Employee
$1,759,267
Profits / Employee
-$197,897
Market Cap
1.84B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,372 | 58 | 4.41% |
| Dec 31, 2023 | 1,314 | 152 | 13.08% |
| Dec 31, 2022 | 1,162 | 322 | 38.33% |
| Dec 31, 2021 | 840 | -26 | -3.00% |
| Dec 31, 2020 | 866 | 123 | 16.55% |
| Dec 31, 2019 | 743 | 244 | 48.90% |
| Dec 31, 2018 | 499 | 244 | 95.69% |
| Dec 31, 2017 | 255 | 58 | 29.44% |
| Dec 31, 2016 | 197 | -73 | -27.04% |
| Dec 31, 2015 | 270 | 66 | 32.35% |
| Dec 31, 2014 | 204 | 58 | 39.73% |
| Dec 31, 2013 | 146 | 43 | 41.75% |
| Dec 31, 2012 | 103 | 5 | 5.10% |
| Dec 31, 2011 | 98 | 0 | - |
| Dec 31, 2010 | 98 | 35 | 55.56% |
| Dec 31, 2009 | 63 | -20 | -24.10% |
| Dec 31, 2008 | 83 | -42 | -33.60% |
| Dec 31, 2007 | 125 | 8 | 6.84% |
| Dec 31, 2006 | 117 | -6 | -4.88% |
| Dec 31, 2005 | 123 | 11 | 9.82% |
| Dec 31, 2004 | 112 | 6 | 5.66% |
| Dec 31, 2003 | 106 | 17 | 19.10% |
| Dec 31, 2002 | 89 | 4 | 4.71% |
| Dec 31, 2001 | 85 | 14 | 19.72% |
| Dec 31, 2000 | 71 | 15 | 26.79% |
| Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 800 |
| MannKind | 407 |
| Vericel | 357 |
| Ocular Therapeutix | 325 |
| Nuvation Bio | 291 |
| Syndax Pharmaceuticals | 270 |
| Aurinia Pharmaceuticals | 130 |
| Stoke Therapeutics | 128 |
SRPT News
- 4 hours ago - Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results - Business Wire
- 7 days ago - Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease - Business Wire
- 15 days ago - Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript - Seeking Alpha
- 16 days ago - Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys - Barrons
- 16 days ago - Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows - Reuters
- 16 days ago - Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Business Wire
- 18 days ago - Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy - Business Wire
- 26 days ago - Sarepta Therapeutics: Is Elevidys A Bust? - Seeking Alpha